文献速递肿瘤 PET/CT

利用突触结合蛋白-I的C2A结构域快速活体成像肿瘤细胞死亡

Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I.
PubMed 文献 · J Nucl Med · 2017-02-16

研究评估了基于突触结合蛋白-I C2A结构域、靶向磷脂酰丝氨酸的探针C2Am用于活体检测肿瘤细胞死亡的效果。在淋巴瘤小鼠模型和人结直肠癌异种移植模型中,近红外荧光标记及99mTc、111In标记的C2Am衍生物均显示主要经肾脏清除,能高特异性、高灵敏度地检测低水平肿瘤细胞死亡(2%-5%),并与cleaved caspase-3等组织学细胞死亡标志物显著相关。

要点

  • 荧光标记C2Am可高特异性、高灵敏度检测2%-5%的肿瘤细胞死亡水平。
  • 99mTc-C2Am和111In-C2Am在给药后24小时主要经肾脏清除,肝脾非特异性滞留低。
  • 99mTc-C2Am在给药后2小时和24小时的肿瘤/肌肉比值分别为4.3倍和7.3倍。

核心结论

  • 鉴于99mTc-和111In标记的C2Am具有良好的生物分布特征,并能产生快速、细胞死亡特异性的图像对比,这些探针具有临床转化潜力。

研究设计与样本

  • 在植入性和基因工程小鼠淋巴瘤模型及人结直肠癌异种移植模型中,评估近红外荧光团标记及99mTc、111In标记的C2Am衍生物经平面近红外荧光成像和SPECT检测肿瘤细胞死亡的能力。

主要发现

  • 荧光团标记的C2Am衍生物主要经肾脏清除,检测低水平肿瘤细胞死亡(2%-5%)具有高特异性和高灵敏度。
  • 荧光标记C2Am结合与包括cleaved caspase-3在内的细胞死亡组织学标志物显著相关(R > 0.9,P < 0.05),而不结合磷脂酰丝氨酸的定点突变体iC2Am无此相关性。
  • 99mTc-C2Am和111In-C2Am在给药后24小时主要经肾脏清除,肝脾非特异性滞留低。
  • 在给药后2小时,99mTc-C2Am和111In-C2Am在药物治疗肿瘤中的肿瘤/肌肉比值分别为4.3倍和2.2倍。
  • 在给药后24小时,99mTc-C2Am和111In-C2Am在药物治疗肿瘤中的肿瘤/肌肉比值分别为7.3倍和4.1倍。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cell death is an important target for imaging the early response of tumors to treatment. We describe here the validation of a phosphatidylserine-binding agent for detecting tumor cell death in vivo based on the C2A domain of synaptotagmin-I. Methods: The capability of near-infrared fluorophore-labeled and 99mTc- and 111In-labeled derivatives of C2Am for imaging tumor cell death, using planar near-infrared fluorescence imaging and SPECT, respectively, was evaluated in implanted and genetically engineered mouse models of lymphoma and in a human colorectal xenograft. Results: The fluorophore-labeled C2Am derivative showed predominantly renal clearance and high specificity and sensitivity for detecting low levels of tumor cell death (2%-5%). There was a significant correlation (R > 0.9, P < 0.05) between fluorescently labeled C2Am binding and histologic markers of cell death, including cleaved caspase-3, whereas there was no such correlation with a site-directed mutant of C2Am (iC2Am) that does not bind phosphatidylserine. 99mTc-C2Am and 111In-C2Am also showed favorable biodistribution profiles, with predominantly renal clearance and low nonspecific retention in the liver and spleen at 24 h after probe administration. 99mTc-C2Am and 111In-C2Am generated tumor-to-muscle ratios in drug-treated tumors of 4.3× and 2.2×, respectively, at 2 h and 7.3× and 4.1×, respectively, at 24 h after administration. Conclusion: Given the favorable biodistribution profile of 99mTc- and 111In-labeled C2Am, and their ability to produce rapid and cell death-specific image contrast, these agents have potential for clinical translation.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Neves AA, Xie B, Fawcett S, et al. Rapid Imaging of Tumor Cell Death In Vivo Using the C2A Domain of Synaptotagmin-I. J Nucl Med. 2017. PMID: 28209913. doi:10.2967/jnumed.116.183004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。